TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32787783
Drug: Prophylactic methoxamine
Normalized name: methoxamine
DrugBank: Methoxamine (DB00723)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic methoxamine infusion (all groups)
Study: 32664033
Drug: Drug expectation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug expectation group (expectation to receive a fast-operating antidepressant)
Study: 32918892
Drug: All pooled
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All pooled treatment groups
Study: 34816288
Drug: Late parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late parenteral nutrition (late-PN)
Study: 616063481
Drug: V+CEF (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: V+CEF (3 cycles of weekly vinorelbine followed by 3 cycles of CEF)
Study: 35581629
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg/day for 6 weeks
Study: 33210997
Drug: Trial preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial preparation (sildenafil tablet 20 mg)
Study: 33210997
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation (sildenafil tablet 20 mg)
Study: 32185595
Drug: CFα late‐start:
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFα late‐start: CFα on day 4 + GnRH antagonist from day 8 + recFSH from day 11 (when needed)
Study: 34725792
Drug: PIEB delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIEB delivered at 125 mL·hr-1 (G125)
Study: 34725792
Drug: PIEB delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIEB delivered at 250 mL·hr-1 (G250)
Study: 32601120
Drug: Bilateral STN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral STN deep brain stimulation (DBS) plus optimal drug therapy (ODT)
Study: 35569129
Drug: Dupilumab (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab (600 mg induction dose, followed by 300 mg every 2 weeks for patients ≥60 kg; 400 mg loading dose followed by 200 mg every 2 weeks for patients <60 kg)
Study: 38588929
Drug: Empagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (10 mg daily)
Study: 33273258
Drug: Prucalopride (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride (2 mg/d before breakfast over 32 weeks)
Study: 33716173
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise (EX) plus 1% testosterone topical gel
Study: 33716173
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise (EX) plus placebo gel
Study: 33905751
Drug: Once-weekly exenatide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly exenatide (EQW)
Study: 33557254
Drug: Dog-assisted therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dog-assisted therapy
Study: 34432394
Drug: Reciprocating automated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reciprocating automated preparation system (WaveOne®) (n = 53)
Study: 34432394
Drug: Rotary preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotary preparation system (ProTaper Next®) (n = 52)
Study: 33866248
Drug: CFI-400945 (PLK4
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFI-400945 (PLK4 inhibitor) combined with radiation therapy
Study: 33866248
Drug: Control or
Normalized name: Dayquil Mucus Control Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control or single-agent treatment
Study: 32672635
Drug: Intra-Tenon injection
Normalized name: tenonitrozole
DrugBank: Tenonitrozole (DB13659)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-Tenon injection of 0.1 ml of 0.01% MMC (TI group)
Study: 35451013
Drug: 1, 2,
Normalized name: Pneumococcal 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1, 2, 4, 8 or 12 µg CG beta added to follitropin delta
Study: 33106225
Drug: Very early
Normalized name: Primula veris extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very early ECMO plus standard pharmacotherapy
Study: 36000541
Drug: Zanidatamab plus
Normalized name: Zanidatamab
DrugBank: Zanidatamab (DB15471)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanidatamab plus chemotherapy
Study: 32536177
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600 mg every 12 hours for 10 days
Study: 33222860
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy (tulathromycin, 2.5 mg/kg subcutaneous)
Study: 35993223
Drug: Adductor canal
Normalized name: Canalevia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adductor canal block (ACB) with 15 mL mixture of ropivacaine 0.2% with isotonic saline and steroids on post-operative day 14 (POD-14)
Study: 34810130
Drug: Concurrent chemotherapy-immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy-immunotherapy with pembrolizumab and multisite radiotherapy
Study: 34810130
Drug: Concurrent chemotherapy-immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy-immunotherapy with pembrolizumab
Study: 36208670
Drug: 10 mM
Normalized name: potassium 10 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mM Ascorbate (non-specific ROS inhibitor)
Study: 36208670
Drug: Ascorbate+L-NAME
Normalized name: L-Ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbate+L-NAME
Study: 33723919
Drug: CBD 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD 0.5 mg/kg
Study: 33723919
Drug: CBD 2
Normalized name: MENTHOL 0.06 g in 1 g TOPICAL GEL [SOMBRA PLUS CBD 2000MG COOL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD 2 mg/kg
Study: 34223660
Drug: CBD (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD (all doses)
Study: 35245416
Drug: Physical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Therapy
Study: 33635382
Drug: Flumazenil infusion
Normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flumazenil infusion
Study: 32887793
Drug: DHA +
Normalized name: PNV-DHA + Docusate Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA + AA supplementation (200 mg DHA + 200 mg AA daily for 180 days)
Study: 34269067
Drug: Tislelizumab plus
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab plus concurrent chemoradiotherapy
Study: 34269067
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus concurrent chemoradiotherapy
Study: 33190032
Drug: Almorexant 200
Normalized name: Nemorexant
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Almorexant 200 mg
Study: 32384291
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg) + Magnesium sulfate (3g)
Study: 36084236
Drug: Levagen+ (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levagen+ (600 mg twice daily for 4 weeks)
Study: 39318719
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice daily for 4 weeks)
Study: 34042543
Drug: Conventional Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Therapy (Control)
Study: 35273049
Drug: High-dose pyrazinamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose pyrazinamide (40 mg/kg) and rifampicin (35 mg/kg) along with standard doses of isoniazid and ethambutol
Study: 35273049
Drug: Standardised TB
Normalized name: TB-402
DrugBank: TB-402 (DB06050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised TB treatment (6-month regimen)
Study: 35273049
Drug: High-dose pyrazinamide-rifampicin
Normalized name: rifampicin, pyrazinamide and isoniazid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose pyrazinamide-rifampicin regimen
Study: 34288106
Drug: Bipolar radiofrequency
Normalized name: quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bipolar radiofrequency treatment
Study: 34288106
Drug: Monopolar radiofrequency
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monopolar radiofrequency treatment
Study: 37231386
Drug: Spinal manipulation
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulation therapy (SMT)
Study: 33184083
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) 400 mg/100 mg two times per day for 5 days
Study: 33184083
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (no treatment)
Study: 33809162
Drug: Sodium hypochlorite
Normalized name: Sodium hypochlorite
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium hypochlorite (NaOCl) treatment for 30 minutes
Study: 33740465
Drug: CC-11050 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-11050 (200 mg twice daily, taken with food; day 1-112)
Study: 33740465
Drug: Everolimus (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (0.5 mg/day; day 1-112)
Study: 33740465
Drug: Auranofin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auranofin (3 mg/day for seven doses, then 6 mg/day; day 1-112)
Study: 34302325
Drug: 200 mL
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mL of plain milk (Control)
Study: 34302325
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation of 200 mL milk fortified with 240 IU of ergocalciferol (vitamin D2)
Study: 33030983
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g leucine (LEU) daily
Study: 39320582
Drug: Tofacitinib 2
Normalized name: tofacitinib 22 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 2 mg BID
Study: 36471444
Drug: 5% lidocaine
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lidocaine patch (LP5)
Study: 35713342
Drug: Add-on treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on treatment
Study: 35713342
Drug: Monotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy treatment
Study: 35999617
Drug: Azithromycin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (20 mg/kg for 3 days; 10 mg/kg for 7 days)
Study: 35689137
Drug: App-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: App-based cognitive behavioral therapy (CBT) program
Study: 32660977
Drug: Ixekizumab (IXE)
DrugBank: Ixekizumab (DB11569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ixekizumab (IXE) monotherapy
Study: 35932230
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g intravenous amoxicillin‐clavulanic acid after the induction of anaesthesia
Study: 36458661
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of trimetazidine dihydrochloride (35 mg)
Study: 36458661
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of trimetazidine dihydrochloride (35 mg)
Study: 35222091
Drug: Sacubitril valsartan
Normalized name: sacubitril / valsartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril valsartan (SV) treatment administered ultra-early (2 hours post-PCI)
Study: 35222091
Drug: Sacubitril valsartan
Normalized name: sacubitril / valsartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril valsartan (SV) treatment administered after 3–7 days post-PCI
Study: 35222091
Drug: Sacubitril valsartan
Normalized name: sacubitril / valsartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril valsartan (SV) treatment
Study: 35401970
Drug: Iron supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplements or iron-containing multiple micronutrient powders (MNPs)
Study: 32696982
Drug: Patch testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch testing in pediatric patients
Study: 32696982
Drug: Patch testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch testing in adult patients (control group)
Study: 33731544
Drug: sacubitril/valsartan 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: sacubitril/valsartan 200 mg bid
Study: 35988178
Drug: Aminophylline treatment
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline treatment
Study: 32585392
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefenamic acid (250 mg)
Study: 36096984
Drug: Tivozanib 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivozanib 1.5 mg orally once daily in 4-week cycles
Study: 33296519
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (16-40 IU/day, twice daily)
Study: 33208878
Drug: Esomeprazole (Eso)
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole (Eso) 40 mg/day
Study: 33217050
Drug: Korean red
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean red ginseng (KRG) 1000 mg/day, n = 26
Study: 32622784
Drug: GLE 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLE 400 mg + PIB 120 mg
Study: 32622784
Drug: GLE 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLE 600 mg + PIB 240 mg
Study: 32299515
Drug: Best practices
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best practices implementation in pancreatic cancer care (including (neo)adjuvant and palliative chemotherapy, pancreatic enzyme replacement therapy, and metal biliary stents)
Study: 32227368
Drug: Fluoxetine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine with cognitive behavioral therapy for 1 year
Study: 32227368
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with cognitive behavioral therapy for 1 year
Study: 35690500
Drug: ASP3772 (1-,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP3772 (1-, 2-, or 5-µg dose per polysaccharide)
Study: 35690500
Drug: PCV13 (13-valent
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV13 (13-valent conjugate vaccine)
Study: 34541683
Drug: Enamel matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enamel matrix derivative (EMD) 0.3 ml
Study: 33732434
Drug: Intranasal esketamine
Normalized name: esketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intranasal esketamine (56mg) administered twice a week for four consecutive weeks
Study: 32858573
Drug: Nadroparin calcium-warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin calcium-warfarin sequential (NWS) therapy (1-month nadroparin calcium by subcutaneous injection followed by 5-month warfarin by oral administration)
Study: 32858573
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no anticoagulation therapy)
Study: 32858573
Drug: NWS anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: NWS anticoagulation therapy
Study: 32858573
Drug: NWS therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NWS therapy group
Study: 35090535
Drug: IV lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV lidocaine infusion (2% lidocaine) for 6–12 hours starting at the beginning of surgery
Study: 35090535
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion for 6–12 hours starting at the beginning of surgery
Study: 34258469
Drug: TOTAL intervention
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOTAL intervention (18-min video highlighting obesity health risks and treatment outcomes)
Study: 33090921
Drug: PRC-063 (methylphenidate),
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRC-063 (methylphenidate), 25 mg/day titrated to maximum 85 mg/day
Study: 35412603
Drug: Japanese Encephalitis
Normalized name: Japanese Encephalitis IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Japanese Encephalitis (JE) vaccine
Study: 35488487
Drug: Brand metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brand metoprolol ER tablets
Study: 35488487
Drug: Drug 1
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug 1 (generic metoprolol ER)
Study: 35488487
Drug: Drug 2
Normalized name: Hartig Drug 29G 1/2 inch Unifine Pentips
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug 2 (generic metoprolol ER)
Study: 35595658
Drug: Durvalumab in
Normalized name: durvalumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab in addition to anthracycline taxane-based neoadjuvant therapy
Study: 34410254
Drug: Proprioception training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proprioception training twice a week for eight weeks along with diabetes awareness lectures once a week
Study: 32207209
Drug: BFR+ (Biofermin-R)
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: BFR+ (Biofermin-R) with VPZ-based therapy
Study: 33407264
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin bilateral medial rectus injections
Study: 34821127
Drug: Tablet Atorvastatin
Normalized name: atorvastatin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet Atorvastatin for 60 days along with lifestyle modification
Study: 37610062
Drug: Imeglimin monotherapy
Normalized name: Fosaprepitant Dimeglumine
DrugBank: Fosaprepitant (DB06717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imeglimin monotherapy at 1,500 mg
Study: 37610062
Drug: Imeglimin monotherapy
Normalized name: Fosaprepitant Dimeglumine
DrugBank: Fosaprepitant (DB06717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imeglimin monotherapy at 2,000 mg
Study: 37610062
Drug: Imeglimin adjunctive
Normalized name: Fosaprepitant Dimeglumine
DrugBank: Fosaprepitant (DB06717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imeglimin adjunctive therapy at 1,000 mg
Study: 37610062
Drug: Imeglimin adjunctive
Normalized name: Fosaprepitant Dimeglumine
DrugBank: Fosaprepitant (DB06717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imeglimin adjunctive therapy at 1,500 mg
Study: 37610062
Drug: Imeglimin (monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imeglimin (monotherapy and adjunctive therapy)
Study: 32900519
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg trans-resveratrol twice-daily for 12 months
Study: 36054038
Drug: Edaravone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone treatment after placebo
Study: 34773302
Drug: Combined photodynamic
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined photodynamic therapy (combPDT)
Study: 34152936
Drug: Conventional photodynamic
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional photodynamic therapy (cPDT)
Study: 35471471
Drug: Low-dose Lingguizhugan
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Lingguizhugan Decoction (LGZG)
Study: 35471471
Drug: Standard-dose Lingguizhugan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose Lingguizhugan Decoction (LGZG)
Study: 34939395
Drug: Shumian capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shumian capsule
Study: 34939395
Drug: Shumian capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shumian capsule simulator (control)
Study: 32212275
Drug: TransCon PTH
Normalized name: TransCon PTH
DrugBank: Palopegteriparatide (DB18676)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TransCon PTH (3.5 to 124 μg PTH(1‐34) for SAD; 3.5 to 24 μg PTH(1‐34)/day for MAD)
Study: 32885276
Drug: Midodrine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine (20 mg orally every 8 hours)
Study: 32885276
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral every 8 hours)
Study: 32885276
Drug: Midodrine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine (20 mg)
Study: 34546088
Drug: Twice-daily intensified
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily intensified rehabilitation training with HBO (Study Group B)
Study: 34546088
Drug: Twice-daily intensified
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily intensified rehabilitation training without HBO (Study Group C)
Study: 33709484
Drug: Forgiveness Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forgiveness Therapy for 24 weeks
Study: 33709484
Drug: Alternative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative treatment for 24 weeks followed by Forgiveness Therapy
Study: 32056414
Drug: G-aenial Universal
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-aenial Universal Flo with self-etch
Study: 32056414
Drug: G-aenial Universal
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-aenial Universal Flo with etch&rinse
Study: 35854250
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy adapted for GAD (CBT-A)
Study: 34403326
Drug: Isoniazid 15
Normalized name: isoniazid 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid 15 mg/kg
Study: 34543941
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + Denosumab
Study: 35037373
Drug: One avocado
Normalized name: Avocado
DrugBank: Avocado (DB10504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One avocado daily for 8 weeks
Study: 34080265
Drug: Cosmos caudatus
Normalized name: Amaranthus caudatus seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cosmos caudatus (CC) supplementation (two 500 mg capsules daily for 12 weeks)
Study: 33847614
Drug: Shenhuang plaster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenhuang plaster application on shenque point (CV8) plus chemotherapy treatment
Study: 34183087
Drug: Tablet-based intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet-based intervention (TBI)